What is Upstream Bio, Inc. (UPB) stock price today?

Upstream Bio, Inc. (UPB) is currently trading at $4.58, up 0.57% today.

What is UPB P/E ratio?

Upstream Bio, Inc.'s P/E ratio is -1.74. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is UPB return on equity (ROE)?

Upstream Bio, Inc.'s return on equity (ROE) is -48.40%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Upstream Bio, Inc.'s market cap?

Upstream Bio, Inc. has a market capitalization of $249.01M.

NMS · Biotechnology

Upstream Bio, Inc. (UPB) Stock

$4.58 +0.57% NMS: UPB Healthcare

Valuation

Metric	Value
Price	$4.58
Market Cap	$249.01M
P/E Ratio	-1.74
P/B Ratio	1.02
P/S Ratio	86.85
EPS (TTM)	$-2.66
52-Week High	$33.68
52-Week Low	$4.41
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-48.40%
ROA	-55.66%
ROCE	-62.68%
Gross Margin	-5333.33%
Operating Margin	-5333.33%
Net Margin	-47.19%
Debt/Equity	0.00
Current Ratio	27.08

Annual Financials (USD)

Metric	2022	2023	2024	2025
Revenue	$1.0M	$2.0M	$2.0M	$3.0M
Operating Profit	$-24.0M	$-40.0M	$-78.0M	$-160.0M
Net Profit	$-24.0M	$-21.0M	$-63.0M	$-143.0M
EPS	$-0.66	$-1.05	$-1.49	$-2.66
Op Margin	-1972.7%	-1685.5%	-3281.2%	-5618.8%

Balance Sheet (USD)

Metric	2022	2023	2024	2025
Total Assets	$18.0M	$117.0M	$482.0M	$354.0M
Total Liabilities	$125.0M	$240.0M	$12.0M	$14.0M
Cash	$17.0M	$26.0M	$326.0M	$102.0M
Borrowings	$0	$0	$2.0M	$1.0M

Latest News

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock? Zacks · Jul 14, 2026 Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage? Insider Monkey · Jun 25, 2026 Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026? Insider Monkey · Jun 23, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 GlobeNewswire · Jun 14, 2026 JPMorgan Downgrades Upstream Bio to Neutral From Overweight, Cuts Price Target to $8 From $35 MT Newswires · Jun 12, 2026

Cash Flow (USD)

Metric	2022	2023	2024	2025
Operating Cash Flow	$-19.0M	$-38.0M	$-59.0M	$-133.0M
Investing Cash Flow	$0	$-83.0M	$-60.0M	$-94.0M
Financing Cash Flow	$0	$0	$-4.0M	$0
Net Cash Flow	$-9.0M	$9.0M	$300.0M	$-224.0M
Free Cash Flow	$-19.0M	$-38.0M	$-60.0M	$-133.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.05
EV / EBITDA	-1.25
FCF Yield	-49.71%
Quick Ratio	27.99
Interest Coverage	0.00
Return 1Y	-44.49%
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held14.88%

Institutions Held88.43%

Institutions Float Held103.88%

Institutional Holder	Shares	Report Date
FMR, LLC	8,101,563	2026-03-31
Orbimed Advisors LLC.	5,693,589	2026-03-31
Blackrock Inc.	3,370,689	2026-03-31
Decheng Capital LLC	2,724,868	2026-03-31
Enavate Sciences Gp, LLC	2,459,703	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AMLXAmylyx Pharmaceuticals, Inc.	$27.96	+2.79%	-19.71	$3.11B	0.00%
NTLAIntellia Therapeutics, Inc.	$12.60	+7.60%	-3.65	$1.76B	0.00%
NVAXNovavax, Inc.	$11.87	+7.77%	-7.38	$1.95B	0.00%
PHVSPharvaris N.V.	$31.46	+1.08%	-10.26	$2.20B	0.00%
RLAYRelay Therapeutics, Inc.	$17.59	+1.01%	-12.08	$3.85B	0.00%

About Upstream Bio, Inc.

Upstream Bio, Inc. is led by CEO E. Rand Sutherland, employs 52 people, headquartered in US, publicly traded since 2024.

Upstream Bio, Inc. (UPB) stock trades at $4.58 with a market capitalization of $249.01M. The stock is valued at a price-to-earnings (P/E) ratio of -1.74, price-to-book of 1.02, price-to-sales of 86.85. Over the past 52 weeks the stock has ranged between $4.41 and $33.68, and currently trades 86.4% below its 52-week high.

On profitability, Upstream Bio, Inc. generates a return on equity (ROE) of -48.40%, return on capital employed of -62.68%, an operating margin of -5333.33%, a net profit margin of -47.19%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1174.49 +0.42% JNJ Johnson & Johnson $261.01 +1.76% ABBV AbbVie Inc. $277.37 +1.82% MRK Merck & Company, Inc. Common Stock (new) $145.82 +2.42% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.36 +2.00% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $658.89 +1.06% AMGN Amgen Inc. $415.88 +2.07% GILD Gilead Sciences, Inc. $151.29 +2.85% ABT Abbott Laboratories $99.18 +0.70% NVO Novo Nordisk A/S $38.39 +0.54%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides